A study presented at the European Renal Association-European Dialysis and Transplant Association meeting found patients with type 2 diabetes and nephropathy who received atrasentan attained improvements in albuminuria and bad cholesterol and triglyceride levels at 12 weeks compared with those who took a placebo. However, the findings merit further and longer-term assessment to see whether the drug would be beneficial, a researcher said.

Related Summaries